Table 1 Baseline characteristics
From: Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
NULMS | ULMS | p value | |
|---|---|---|---|
n (%) or median (range) | n (%) or median (range) | ||
N | 50 (100%) | 45 (100%) | |
Age at first diagnosis | 61 (31-88) | 54 (32-69) | 0.002 |
Gender | <0.001 | ||
- Male | 28 (56%) |
| |
- Female | 22 (44%) | 45 (100%) | |
Tumor stage | |||
- FIGO I |
| 15 (33%) | |
- FIGO III |
| 3 (7%) | |
- FIGO IV |
| 27 (60%) | |
Histological grade | n = 47 | n = 34 | 0.027 |
- G 1 | 1 (2%) | 3 (9%) | |
- G 2 + 3 | 46 (98%) | 31 (91%) | |
Tumor site | n = 50 | ||
- Extremities | 30 (60%) |
| |
- Abdominal | 16 (32%) |
| |
- Head/neck | 2 (4%) |
| |
- Thorax | 2 (4%) |
| |
Tumor size | n = 50 | n = 45 | <0.001 |
cm | 11.1 (3-40) | 6.7 (3-14) | |
- ≤5 cm | 23 (46%) | 6 (13%) | |
- 5-10 cm | 22 (44%) | 14 (32%) | |
- > 10.0 cm | 5 (10%) | 19 (42%) | |
- Not evaluable |
| 6 (13%) | |
Tumor location | n = 50 | ||
- Deep/superficial | 37 (74%)/13 (26%) |
| |
Initial metastatic disease | 0.007 | ||
- Yes | 18 (36%) | 30 (67%) | |
Metastatic sites | n = 18 | n = 30 |
|
- Lung | 14 (28%) | 17 (38%) | |
- Liver | 7 (14%) | 5 (11%) | |
- Bone | 4 (8%) | 4 (9%) | |
- Lymph nodes | 3 (6%) | 8 (18%) | |
- Other | 5 (10%) | 15 (33%) | |
Surgical resection | 0.2 | ||
- Yes | 47 (94%) | 45 (100%) | |
Resection margins | n = 47 | n = 45 | 0.048 |
- Wide | 45 (96%) | 37 (82%) | |
- Marginal | 2 (4%) | 8 (18%) | |
Re-resection | |||
- Yes | 16 (34%) |
| |
Pulmonary metastaseectomy | 0.6 | ||
- Yes | 6 (12%) | 8 (18%) | |
Radiationtherapy | 0.04 | ||
- Yes | 29 (58%) | 16 (36%) | |
Adjuvant Chemotherapy for initially localized disease |
| ||
- Yes | 13 (41%) | 8 (53%) | |
Chemotherapy Regimen for initially localized disease |
| ||
- Epirubicine/ifosfamide | 6 (46%) | 3 (37%) | |
- Doxorubicine | 5 (39%) | 1 (13%) | |
- IFADIC | 2 (15%) | 2 (25%) | |
- Gemcitabine/docetaxel | 0 | 2 (25%) | |
Relapse |
| ||
- No | 12 (92%) | 6 (75%) | |
- Yes | 1 (8%) | 2 (25%) | |
First line chemotherapy for initially metastastic disease |
| ||
- Yes | 18 (36%) | 27 (60%) | |
First line chemotherapy regimen for initially metastastic disease | n = 18 | n = 27 |
|
- Doxorubicine | 9 (50%) | 7 (27%) | |
- Epirubicine/ifosfamide | 6 (33%) | 2 (7%) | |
- IFADIC | 0 | 3 (11%) | |
- Other | 3 (17%) | 2 (7%) | |
- Gemcitabine/docetaxel |
| 13 (48%) | |
Response to first line Chemotherapy for initially metastastic disease | n = 18 | n = 27 |
|
- Complete remission | 4 (22%) | 2 (7%) | |
- Partial remission | 2 (11%) | 3 (11%) | |
- Stable disease | 4 (22%) | 4 (15%) | |
- Progressive disease | 7 (39%) | 18 (67%) | |
- Not evaluable | 1 (6%) |
| |
Follow-up time (months) | 50 (1.2-153.7) | 33 (1.5-269.1) | |
Disease status | |||
Alive/dead | 38 (76%)/12 (24%) | 20 (44%)/25 (56%) |
